Stockwinners Market Radar for February 04, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:14 EST Dish, Tegna reach new carriage agreement - DISH Network announced it reached a new carriage agreement with Tegna. Local stations have been immediately restored on DISH TV, in time for the Winter Olympics and Super Bowl LVI. The agreement provides DISH TV subscribers nationwide the ability to tune in to Tegna-owned programming, including news, entertainment and sports.

17:21 EST Peloton jumps 29% after WSJ report that Amazon.com is among potential buyers - In after-hours trading, shares of Peloton are up 29% to $31.77.

17:02 EST Longview Acquisition II, HeartFlow terminate merger agreement - HeartFlow announced that it and Longview Acquisition II, a special purpose acquisition company sponsored by affiliates of Glenview Capital Management, have mutually agreed to terminate their previously announced business combination agreement, effective immediately, as a result of current unfavorable market conditions.

16:57 EST Gol Linhas reports preliminary January total supply up 26.2% y/y - GOL Linhas Aereas Inteligentes S.A. announced preliminary air traffic figures for the month of January 2022, compared to the same period in 2021. GOL's total supply increased 26.2%. Total seats increased 29.8% and the number of departures increased by 29.3%. GOL's total demand increased by 25.2% and the load factor was 82.6%. GOL's domestic supply increased 22.2% and demand increased by 21.5%. GOL's domestic load factor was 82.8%. The volume of departures increased by 27.4% and seats increased by 27.9%. GOL's international supply was 132 million, the demand was 102 million and international load factor was 77.4%.

16:43 EST Discovery sees DTC business achieving profitability by 2025 - In a regulatory filing, Discovery (DISCA) said that, following its transaction with WarnerMedia (T), it adjusted long-term projections. The material estimates and assumptions made by Discovery management in connection with the preparation of the Discovery Management Projections include: Compared to forecast 2021 levels and reflecting broader trends of a shift to DTC delivery by 2025, Revenue decreasing by approximately 4% annually and operating expense growth of approximately 3% annually in the U.S. linear business; Revenue decreasing by approximately 3% annually and operating expense decreasing by approximately 3% annually in the international linear business; DTC business, led by discovery+, achieving scale and profitability by 2023 and approaching 20% expected long-term margins by 2025; and total content spend increasing to $4.0 billion in 2025. The material estimates and assumptions made by Discovery management in connection with the preparation of the Discovery Advocacy Projections, as compared to the Discovery Management Projections, include: Better cost containment within the U.S. linear business, contributing to operating expense growth of approximately 1% annually; Tempered trends within the international business, with revenue decreasing by approximately 1% annually and operating expense decreasing by approximately 2% annually; Higher revenue and margin growth in the DTC business, approaching 25% expected long-term margins by 2025; and total content spend increasing to $4.2 billion in 2025.

16:32 EST Ion Geophysical receives continued listing standard notice from NYSE - ION Geophysical Corporation announced that it received notice on January 31, 2022 from the New York Stock Exchange that the price of its common stock fell below the NYSE's continued listing standards. The NYSE requires that the average closing price of a listed company's common stock remain above $1.00 per share over a consecutive 30 trading-day period. As of January 28, 2022, the 30 trading-day period average closing price of the company's common stock was $0.94 per share. In accordance with NYSE rules, the company must notify the NYSE within 10 business days of receipt of the notification with its intent to cure the deficiency. The company has six months to regain compliance with the NYSE continued listing requirements. During the six-month period, the company's common stock will continue to be listed and traded on the NYSE, subject to compliance with other continued listing standards. The deficiency does not affect the company's ongoing business operations or its SEC reporting requirements.

16:25 EST Alcoa CIO Kahrs sells 15,376 common shares - In a regulatory filing, Alcoa executive VP and chief innovation officer Benjamin Kahrs disclosed the sale of 15,376 common shares of the company on February 2 at a price of $59.0353 per share.

16:16 EST ObsEva says more questions on linzagolilx MAA may be forthcoming from EMA - ObsEva announced that based on ongoing communications with the European Medicines Agency, further questions on the marketing authorisation application for linzagolix may be forthcoming, thereby extending the application timeline. ObsEva is in dialogue with the EMA to understand areas that may require further clarification and is committed to promptly addressing any questions that could arise. In the United States, the New Drug Application for linzagolix for the treatment of uterine fibroids has been accepted for review by the United States Food and Drug Administration (FDA), with a PDUFA target action date of September 13, 2022.

15:58 EST Otter Tail raises quarterly dividend 5.8% to 41.25c per share - The dividend is payable on March 10 to shareholders of record on February 15.

15:08 EST FDA approves Enjaymo for adults with rare type of anemia - The FDA has approved Enjaymo, sutimlimab-jome, infusion to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease, or CAD, a rare disease affecting about one person per million annually, which mostly develops in individuals between ages 40 and 80 years. The Biologics License Application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease was submitted by Sanofi. Reference Link

14:15 EST Wi-LAN says appeals court confirms Apple infringes patents - Wi-LAN, a Quarterhill (QTRHF) company, provided an update on ongoing litigation, stating: "In a decision issued today by the United States Court of Appeals for the Federal Circuit, or the 'CAFC,' the three-judge panel ruled in WiLAN's favor regarding several of WiLAN's arguments. First, the CAFC agreed with WiLAN's claim construction arguments relating to the patents-in-suit. Second, the CAFC ruled in WiLAN's favor with respect to WiLAN's infringement related arguments. Notably, Apple did not appeal the lower court's decision that WiLAN's patents are valid over the prior art. With these two rulings today, the CAFC has conclusively decided that Apple infringes the patents-in-suit and is liable to pay damages to WiLAN. In addition, the CAFC also ruled in WiLAN's favor regarding a prior license agreement between Intel Corp. and WiLAN. This prior license was dealt with in a summary judgment of non-infringement decision previously issued by the United States District Court of the Southern District of California from which this appeal was being heard. In that summary judgment ruling, the District Court had ruled that Apple products using Intel wireless chips should be excluded from the damages calculations that were awarded to WiLAN. In its ruling today, the CAFC disagreed with that District Court decision and instead agreed with WiLAN's position, making Intel-based Apple products available for inclusion in a final damages award. Finally, the CAFC ruled against WiLAN with respect to certain assumptions made by WiLAN's damages expert in calculating the damages amount that was presented to the jury. As a result, the CAFC has remanded the case back to the District Court for another trial focusing on the amount of damages that Apple will be required to pay." Michael Vladescu, President and CEO of WiLAN, added: "Overall, we see the CAFC decision as favorable to WiLAN and consistent with the arguments heard at Oral Argument. We remain committed and focused on advocating our positions which we believe are fair and balanced. At the same time, we always remain open to resolving any litigation disputes through reasonable negotiated solutions."

13:19 EST Macellum Advisors confirms plans to nominate slate to Kohl's board

13:15 EST Coinbase investigating latency on Coinbase.com and mobile app - Coinbase stated in a message posted to its status page: "We're investigating latency on Coinbase.com and the mobile app and increased trade failures. We are currently investigating this issue." Reference Link

13:00 EST Baker Hughes reports U.S. rig count up 3 to 613 rigs

12:29 EST TEGNA trading resumes

12:24 EST TEGNA trading halted, volatility trading pause

12:01 EST Gelesis falls -10.9% - Gelesis is down -10.9%, or -60c to $4.88.

12:00 EST Clorox falls -14.2% - Clorox is down -14.2%, or -$23.40 to $141.94.

12:00 EST Bill.com rises 31.8% - Bill.com is up 31.8%, or $54.11 to $224.39.

11:59 EST Nintendo reports over 6.5M players globally so far for 'Pokemon Legends: Arceus' - Nintendo of America tweeted that over 6.5M players worldwide have already played "Pokemon Legends: Arceus" since its January 28, 2022 release. The game is a Nintendo Switch exclusive title. Reference Link

11:17 EST BioMarin: Valoctocogene roxaparvovec improved bleed free rate in trial - BioMarin Pharmaceutical announced that the company presented results from a two-year analysis of the Phase 3 GENEr8-1 study and an overall safety update of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders. This is the largest global Phase 3 study to date for any gene therapy in hemophilia with 134 participants, BioMarin said. In the GENEr8-1 Phase 3 study, Annualized Bleeding Rate was significantly reduced by 4.1 treated bleeds per year, or by 85% from a baseline mean of 4.8, in the pre-specified primary analysis in participants from a prior non-interventional study. The percentage of participants with zero treated bleeds increased from 32% on prophylaxis at baseline to 82% during year 1 and 84% during year 2. The mean ABR was 0.8 through the entire efficacy evaluation period, 0.9 during year one, and 0.7 during year two. Across all participants in the rollover population, mean annualized Factor VIII infusion rate was reduced by 133 infusions per year or 98% from baseline. As of the two-year data cut, 95% of participants remain off Factor VIII prophylactic therapy.

11:01 EST Anghami completes business combination with Vistas Media Acquisition - Anghami ANGH, a music streaming platform and service in the Middle East and North Africa, announced that is has completed its business combination with Vistas Media Acquisition Company. Anghami's common ordinary shares and its warrants will begin trading in the United States on February 4, 2022 on NASDAQ under the tickers "ANGH" and "ANGHW," respectively. Eddy Maroun, Co-founder and Co-CEO of Anghami, commented, "Today marks the end of a long journey toward listing on NASDAQ, but also the momentous beginning of our life as a publicly traded company. We are grateful to our investors and partners who have made this possible. We believe that our efforts to take a different approach and challenge the status quo in the streaming world present a great opportunity for fans not only in the region, but also for millions of people around the world who are trying to reconnect with their roots through music. As we embark on this new chapter, we remain as committed as ever to our goal of expanding the Arabic-language music repertoire through new initiatives and innovative concepts such as Anghami Originals, Anghami Labs, live concerts, live radio and branded content."

10:42 EST Apple, Broadcom Wi-Fi patent fight with Cal Tech remanded for new trial - The U.S. Court of Appeals for the Federal Circuit vacated a $1.1B verdict that the California Institute of Technology was previously awarded in a fight with Apple (AAPL) and Broadcom (AVGO) over infringement on patents for Wi-Fi technology and remanded the case for a new trial on damages. A prior two-tier damage award of $270.2M against Broadcom and $837.8M against Apple is "legally unsupportable," the appeals court has ruled.

10:25 EST CSL Behring announces long-term results from Phase 3 HOPE-B trial - CSL Behring announced long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec, an investigational adeno-associated virus five-based gene therapy for people living with hemophilia B, a life-threatening bleeding disorder. Following a single infusion of etranacogene dezaparvovec, participants experienced a stable and durable increase in mean Factor IX activity and hemostatic protection at 18 months. The final data, from the largest gene therapy study in hemophilia B, were presented as part of the latest clinical trial results session at the European Association of Haemophilia and Allied Disorders 2022 Annual Meeting. The Phase 3, open label, single-dose, single arm HOPE-B trial, which included 54 male participants with severe or moderately severe hemophilia B, demonstrated that etranacogene dezaparvovec produced mean FIX activity of 39.0 IU/dL at six months and 36.9 IU/dL at 18 months post infusion. After the six-month lead-in period post-infusion, the adjusted annualized bleeding rate for all bleeds was reduced by 64 percent and all FIX-treated bleeds was reduced by 77 percent over months seven to 18. In addition, 98 percent of subjects treated with a full dose of etranacogene dezaparvovec discontinued use of prophylaxis, with an overall 97 percent reduction in mean unadjusted annualized FIX consumption of 257338.8 IU/yr/participant to 8486.6 IU/yr/participant. Etranacogene dezaparvovec is generally well-tolerated with the majority of adverse events considered mild. One death resulting from urosepsis and cardiogenic shock in a 77-year-old patient at 65 -weeks following dosing was considered unrelated to treatment by investigators and the company sponsor. A serious adverse event of hepatocellular carcinoma was determined, by independent molecular tumor characterization and vector integration analysis, to be unrelated to treatment with etranacogene dezaparvovec. No inhibitors to FIX were reported.

10:13 EST Biden extends tariffs on imported solar equipment another four years - President Joe Biden this morning extended the tariffs on imported solar equipment but left in place an exemption for imported two-sided, or bifacial, panels. The tariffs had been scheduled to expire in early February and will now run for another four years, under Biden's proclamation. Former President Donald Trump introduced the tariffs in 2018. Biden is also doubling the allowable import quota for duty-free solar cells to 5 gigawatts, enabling companies to import proprietary cells. Publicly traded companies in the solar space include Array Technologies (ARRY), Canadian Solar (CSIQ), FTC Solar (FTCI), First Solar (FSLR), JinkoSolar (JKS), Maxeon Solar (MAXN), ReneSola (SOL), Shoals Technologies (SHLS), SolarEdge (SEDG) and SunPower (SPWR). Reference Link

10:01 EST Ford falls -10.0% - Ford is down -10.0%, or -$1.98 to $17.91.

10:00 EST Universal Technical rises 11.7% - Universal Technical is up 11.7%, or 87c to $8.32.

10:00 EST Snap rises 45.5% - Snap is up 45.5%, or $11.14 to $35.64.

09:47 EST Ford falls -8.8% - Ford is down -8.8%, or -$1.75 to $18.14.

09:47 EST Universal Technical rises 11.3% - Universal Technical is up 11.3%, or 84c to $8.29.

09:47 EST Snap rises 49.0% - Snap is up 49.0%, or $12.01 to $36.51.

09:17 EST Medigus purchases 40% of Israeli drone technology company - Medigus announced that it has purchased approximately 40 percent of an Israeli drone technology company with a patented safety system for drones. The company said, "This Israeli-drone company has developed a patented drone safety system which is designed to protect people and payloads, providing a solution to reduce the risk of a drone's possible malfunction in an urban environment. Unique in the industry, the system includes a smart parachute that monitors drone flight in real time, identifies critical failures, and autonomously triggers a parachute in the event of an emergency. This innovative solution aims to prevent the loss of drones that malfunction and crash, which potentially could save commercial drone operators millions in losses." The drone company's safety technology is ASTM F3322-18 compliant parachute system for the DJI Mavic 2 and Phantom 4 series. ASTM F3322-18 requires over 45 aerial parachute deployments with a third-party testing agency. Together with the standard's other requirements, these tests give operators and regulators the confidence required in the three performance pillars of a parachute system: effective and reliable in all failure scenarios, rated descent rate, and minimum flight altitude. The commercialization phase is underway with sales and deliveries to initial customers throughout a global distribution footprint which aims to sell the drone safety system for various types of drones and unmanned aerial vehicles.

09:08 EST Kohl's adopts limited-duration shareholder rights plan - Kohl's announced that it has adopted a limited-duration shareholder rights plan, which is effective immediately and which is scheduled to expire on February 2, 2023. "The rights plan has been adopted in order to ensure that the Board of Directors can conduct an orderly review of expressions of interest, including potential further engagement with interested parties. The rights plan does not preclude the Board from considering an offer that recognizes the value of the Company," Kohl's said in a statement. The dividend distribution of one right for each outstanding share of the company's common stock is payable to shareholders of record on February 14. The rights will be exercisable only if, following the time of this announcement, a person or group acquires beneficial ownership of 10% or more of the outstanding common stock. In that case, each holder of a right will be entitled to purchase, at the then-current exercise price, additional shares of the company's common stock at a 50% discount. Any shareholders with ownership of the company's outstanding common stock above the applicable threshold as of the time of this announcement are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the rights plan. "The rights plan provides several important shareholder-friendly features, including an ability for shareholders to call a special meeting for purposes of exempting a 'qualifying offer,'" Kohl's said.

09:06 EST DTE Energy to add new MIGreenPower renewable energy project - DTE Energy announced that it will add new renewable energy projects totaling approximately 500 megawatts due to the continued growth and popularity of its MIGreenPower voluntary renewable energy program. "We want to thank all of our MIGreenPower customers for their participation in the program," said Trevor Lauer, president and chief operating officer of DTE's electric company. "Over the next decade, we plan to continue adding clean energy projects and investing in new technologies to move our state closer to a carbon neutral future." As a result of MIGreenPower customer commitments, DTE is issuing a Request for Proposals, RFP, for new wind and solar projects, both with and without energy storage. The projects must be ready to achieve commercial operation in 2023, located in Michigan, and interconnected to the Midcontinent Independent System Operator, MISO, or distribution level transmission. MIGreenPower enrollment has doubled for each of the past three years and is having a direct impact on the number of new clean energy projects DTE is bringing online.

09:04 EST Riot Blockchain expects self-mining hash rate capacity of 12.8 EH/s by Q4 - By Q4 2022, Riot anticipates a total self-mining hash rate capacity of 12.8 EH/s, assuming full deployment of approximately 120,150 Antminer ASICs, but excluding any potential expected incremental productivity gains from the Company's utilization of 200 MW of immersion-cooling infrastructure. Approximately 97% of Riot's self-mining fleet will consist of the latest generation S19 series miner model. Upon full deployment of all currently contracted miners, the Company's total self-mining fleet will consume approximately 370 MW of energy. In addition to the Company's self-mining operations, Riot's Whinstone Facility hosts approximately 200 MW of institutional Bitcoin mining clients.

09:04 EST Riot Blockchain announces January production, operations update - Riot Blockchain announces production and operations update for January 2022, updates to the status of miner shipments and deployment, updates on the 400 megawatt infrastructure expansion at the Company's Whinstone US facility in Rockdale, Texas, and an update on remaining flexible for the ERCOT power grid stabilization. "Riot is well-positioned for continued growth and production in 2022," said Jason Les, CEO of Riot Blockchain. "We are pleased to share that miner deployments in one of our immersion-cooled buildings are now fully underway. We have refined our process for driving immersion-based miner installations and are now initiating tests on productivity enhancements supported by this cooling technology. We expect to see increases in our hash rate capacity as we continue to execute on deployments in the newly completed Building F and the soon to be completed, Building G." Production Updates: In January 2022, Riot produced 458 BTC, an increase of approximately 252%, as compared to the January 2021 production of 130 BTC. As of January 31, 2022, Riot held approximately 5,347 BTC, all produced by the Company's self-mining operations. Riot currently has a deployed fleet of approximately 32,552 miners, with a hash rate capacity of 3.4 exahash per second.

09:02 EST Blue Bird to implement 4% price increase for Type C, D model activity - Blue Bird announced that it will implement a price increase to offset rising material, freight and labor costs primarily driven by the global COVID-19 pandemic. The 4% total price increase will impact all net selling prices for Type C and Type D model activity and school buses ordered on or after Tuesday, March 1. "As we enter 2022, the school bus industry continues to face challenging and unprecedented times," said Matthew Stevenson, President and CEO of Blue Bird Corporation. "According to a recent Labor Department report, inflation grew by 7% in 2021, the fastest 12-month increase in nearly 40 years. We continue to work with our supplier partners to limit the negative impact, but felt it was necessary to make this adjustment to our bus pricing. In addition, we have discussed the challenging business environment with our Dealer Advisory Council. We will continue to be transparent with all of our loyal Blue Bird customers and remain committed to building best-in-class school buses."

08:46 EST Lakeside Book to acquire ALJ Regional Holdings' Phoenix Color - Lakeside Book and ALJ Regional Holdings announced that they have entered into a definitive agreement for Lakeside's acquisition of all of the issued and outstanding shares of common stock of ALJ's wholly-owned subsidiary Phoenix Color. Headquartered in Hagerstown, Maryland, Phoenix is a specialty printer of book components, children's books, and other print-related products with printing facilities in Indiana and Maryland. The transaction is expected to close during the Q2, subject to customary closing conditions and regulatory and stockholder approvals.

08:42 EST Scotts Miracle-Gro announces expiration, results of exchange offer - The Scotts Miracle-Gro Company announced the expiration and results of its previously announced registered exchange offer to exchange any and all of its $500,000,000 aggregate principal amount of 4.000% Senior Notes due 2031, which were issued in a private placement on March 17, 2021, for an equal principal amount of its 4.000% Senior Notes due 2031, which have been registered under the Securities Act of 1933, as amended. The exchange offer expired at 11:59 p.m., New York City time, on February 3, 2022. As of that time, $474,981,000 aggregate principal amount, or approximately 95.0%, of the Original Notes had been validly tendered for exchange and not validly withdrawn. All of the Original Notes validly tendered and not validly withdrawn were accepted for exchange in the exchange offer. The Company expects that settlement of the exchange offer will occur on or about February 9, 2022. The exchange offer was made to satisfy the Company's obligations under a registration rights agreement entered into on March 17, 2021 in connection with the issuance of the Original Notes, and does not represent a new financing transaction. The exchange offer was made upon the terms and conditions set forth in the exchange offer documents distributed to holders of the Original Notes, including a prospectus dated December 22, 2021 and the related letter of transmittal.

08:36 EST SES to trade on NYSE under symbol 'SES' following completion of SPAC deal - SES AI Corporation, which is engaged in the development and production of high-performance lithium-metal rechargeable batteries for electric vehicles and other applications, announced that its Class A common stock and warrants will begin trading on the New York Stock Exchange today under the ticker symbols "SES" and "SES.WS", respectively, following the completion of a business combination with Ivanhoe Capital Acquisition Corp. (IVAN). "Today we celebrate an important milestone in a journey that we began a decade ago as a spin-out company of the Massachusetts Institute of Technology. Now we're a leading global developer and producer of high-performance Li-Metal batteries with investments from six major global car manufacturers and 'A-sample' joint development agreements with three of them," said Qichao Hu, SES Founder and CEO.

08:33 EST Nathan's Famous board raises quarterly cash dividend 29% to 45c per share - Effective February 4, 2022, the Board of Directors increased the quarterly cash dividend by 29% and declared a quarterly cash dividend of $0.45 per share payable on March 4, 2022 to shareholders of record at the close of business on February 21, 2022.

08:10 EST Independence Holding declares dividends related to going-private transaction - Independence Holding Company announced that its Board of Directors has declared a prorated dividend on the Company's shares of common stock, contingent upon the consummation of the merger of Geneve Acquisition Corp., an indirect wholly-owned subsidiary of Geneve Holdings, with and into the Company, resulting in the Company being an indirect wholly-owned subsidiary of Geneve. If the requisite stockholder approvals to consummate the Merger are received at the special meeting of stockholders of the Company to be held on February 15, 2022, the contingent prorated dividend will be payable in cash to the Company's stockholders of record as of the close of business on February 15, 2022, payable on February 22, 2022, contingent upon the consummation of the Merger. If the requisite stockholder approvals to consummate the Merger are not received at the Special Meeting, the Record Date will automatically be changed to be the date of the subsequent special meeting at which the Merger is approved, and the Payment Date will automatically be changed to the date that is five business days after such new Record Date, contingent upon the consummation of the Merger. The amount of the contingent prorated dividend, on a per share basis, is expected to be $.06 per share, but the actual amount of the dividend will be based on a formula equal to $0.44 multiplied by the number of days between, and including, December 28, 2021, which is the payment date of the last regular dividend paid by the Company and the date of the closing of the Merger, divided by 365. Because the payment of the dividend is contingent on the closing of the Merger, shareholders must continue to hold their shares of common stock through the closing of the Merger in order to receive the special dividend. As described in the definitive proxy statement filed by the Company on January 6, 2022, the Merger requires, among other things, the approval of both the holders of a majority of the issued and outstanding shares of the Company's common stock at the close of business on January 3, 2022, and the holders of a majority of the issued and outstanding shares of the Company's common stock at the close of business on January 3, 2022 other than shares of common stock held by Geneve and its wholly-owned subsidiaries or beneficially owned by any affiliate of Geneve. There can be no assurance that the Merger will be consummated.

08:07 EST Royal Caribbean expects 1H22 load factors to remain below historical levels - The travel industry has experienced significant short-term disruptions due to the omicron variant. Such disruptions intensified during the holiday season and in early January, with the spread of the variant, and impacted the company's cancellations and bookings for near-term sailings. Load factors for sailings in the first half of 2022 are expected to remain below historical levels, consistent with the company's return to service schedule, which includes the impact from Omicron. Load factors for sailings in the second half of 2022 continue to be booked within historical ranges, at higher prices with and without FCCs. "Following a record U.S. black Friday and cyber weekend, the spread of the Omicron variant resulted in a softening in booking volumes and an increase in near-term cancellations," said Holtz. "Similar to our experience following Delta, we expect bookings to materially increase as we get further beyond the peak of cases. We are already seeing cancellations subside and bookings improve to pre-Omicron levels, and we have adjusted our sales and marketing efforts in anticipation of a delayed and extended WAVE period." The company is excited about the introduction in 2022 of two new ships, Wonder of the Seas and Celebrity Beyond. These new ships add to the six new ships that joined the fleet over the last 20 months and are expected to be important contributors to yield growth and profitability. As of December 31, 2021, the company had approximately $3.2 billion in customer deposits. This represents an improvement of about $400 million over the previous quarter despite the significant quarter-over-quarter increase in revenue recognition and near-term cancellations due to Omicron, both of which reduce the customer deposits balance. The customer deposit balance at year-end for Q2 2022 forward sailings was higher than the balance held at the end of 2019 for Q2 2022 forward sailings. Approximately 32% of the customer deposit balance is related to FCCs compared to 35% in the prior quarter, a positive trend indicating new demand.

08:06 EST Disney delays maiden voyage of new Disney Cruise Line ship to July 14 - The maiden voyage of the new Disney Cruise Line ship, Disney Wish, has been delayed from June 9 to July 14, 2022, Disney announced. Guests booked for the maiden voyage will be auto-booked onto the new one, it said.

08:05 EST Navitas Semiconductor announces redemption of outstanding warrants - Navitas Semiconductor announced that it will redeem all of its publicly traded and privately held warrants to purchase shares of Navitas' Class A common stock that remain outstanding at 5:00 p.m. New York City time on March 7, 2022, for a redemption price of $0.10 per warrant. Navitas has directed its warrant agent, Continental Stock Transfer & Trust Company, to deliver a Notice of Redemption to the registered holders of outstanding warrants pursuant to the Warrant Agreement, dated as of December 2, 2020, by and between Navitas and the Warrant Agent. Under the Warrant Agreement, Navitas is entitled to redeem its public warrants at a redemption price of $0.10 per warrant if the closing price of its common stock has been at least $10.00 per share on any 20 trading days within the 30-trading-day period ending three business days before notice of the redemption is given, among other conditions. If Navitas elects to exercise that right, the warrant terms require the company to concurrently redeem the privately held warrants if the closing price of its common stock on any 20 trading days within the same 30-trading-day period is less than $18.00 per share. Both stock price conditions were satisfied as of February 1, 2022, the third business day before the Notice of Redemption is being sent to warrant holders.

08:04 EST Oxford Lane estimates January NAV $6.98-$7.08 - Oxford Lane Capital announced the following net asset value estimate as of January 31, 2022. Management's unaudited estimate of the range of the NAV per share of our common stock as of January 31, 2022 is between $6.98 and $7.08. This estimate is not a comprehensive statement of our financial condition or results for the month ended January 31, 2022. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending March 31, 2022 may differ materially from this estimate, which is given only as of January 31, 2022. As of January 31, 2022, the Company had approximately 131.4 million shares of common stock issued and outstanding.

08:01 EST Arqit Quantum signs cooperative research, development agreement with USAF - Arqit has signed a new Cooperative Research and Development Agreement, CRADA, with the US Air Force's, USAF, Research Laboratory, Directed Energy Directorate, Space Electro-Optics Division. The CRADA will demonstrate the interoperability and performance of Arqit's QuantumCloud platform for defense use cases. Under the agreement, a variety of performance measures and interoperabilities will be examined to demonstrate and validate the contribution that QuantumCloud can make to DoD facilities. The expected outcome of the CRADA is to prove viable quantum encryption services from a commercial platform to DoD infrastructure for USAF and wider DoD use cases. Arqit Founder, Chairman and CEO David Williams said: "We are honoured to sign a CRADA with the USAF. They have a fantastic pedigree for embracing and developing pioneering technology and given its lead status in areas like directed energy, cyber warfare, and Joint All-Domain Command and Control, the USAF is the perfect partner for us not only in developing applications for US Government users but also for other Five-Eyes partners."

07:54 EST Vanda drops 22% to $11.40 after Phase 3 tradipitant study did not meet endpoint

07:38 EST Purple Biotech CEO says 2022 will be 'monumental year' for company - Purple Biotech issued a letter from its CEO Isaac Israel, to its shareholders, which read in part, "I look back at 2021 proudly as a foundation-setting year for Purple Biotech, one with clinical development achievements, personnel and culture advancements. Through our collaborations, products and people, we continue to advocate for and work towards the realization of our mission to move individuals from cancer patients to cancer survivors. I am pleased with the meaningful progress we have made toward our goals and want to take this moment to share highlights of this year...Our strategic approach continues to be the development of cancer treatments addressing not only the tumor itself but also the tumor microenvironment to improve patient outcomes. We believe our vision and passion for viewing cancer treatment through a lens focused within the components of the tumor microenvironment allows us to be well-positioned for a differentiated and successful clinical outcome. 2022 will continue to be a year of clinical development emphasis for our pipeline assets. Our preliminary trial data in 2021 allowed significant learnings for building this year, creating new opportunities for advancing our primary assets with the expansion of trial arms for both product candidates....We have entered a pivotal year for our lead assets, CM24 and NT219. As we look back on 2021, our clinical development has progressed as anticipated, with encouraging initial data readouts from both of our lead candidates, to be articulated at upcoming major medical meetings. Current clinical development of these programs will continue as planned in 2022. Furthermore, we plan to expand the programs into new indications and share data milestones at the appropriate venues in 2022. With CM24, our first-in-class clinical stage mAb targeting CEACAM1, we will deliver our Phase 1b data readout at an upcoming medical conference. Further, we have announced a planned expansion arm for RP2D, initiated in Q1 of 2022. CM24 continues to be an exciting program for Purple Biotech. We are encouraged by the initial data released during ESMO 2021 from our ongoing Phase 1b/2 clinical trial of CM24 in combination with nivolumab, demonstrating safety and a partial response in a 3rd line pancreatic cancer patient, one of the first three patients treated with the first dose level. Purple Biotech continues to lead the field of CEACAM1-targeted therapies with the most advanced clinical asset in this area. In 2022, we will look to study CM24 in combination with other agents, in patients with other types of cancers, in addition to the current arms in NSCLC and pancreatic cancer. Considering NT219, our first-in-class novel small molecule targeting IRS1/2 and STAT3 simultaneously, we anticipate a readout on our Phase 1 monotherapy data in the first half of this year. This data will build on our data milestone release from ASCO 2021, which presented a partial response in one patient in the first three patients treated with the first and the lowest dose level. Following the completion of the third dose level in the monotherapy arm, we initiated the dose escalation arm to treat squamous cell carcinoma head and neck as well as colorectal cancer patients with NT219 in combination with cetuximab. In addition, the expansion arm on RP2D in combination with cetuximab in SCCHN patients will initiate in 2022. Later in the year, we plan to expand the evaluation of NT219 in combination with other treatments in other cancer patients. We believe that NT219 has the potential to be a key anti-cancer agent addressing the drug resistance phenotype. Purple Biotech continues to be the first and leading company to successfully target the IRS protein to degradation and focused on a dual-inhibition MOA approach of both IRS and STAT3...We believe that 2022 will be a monumental year for Purple Biotech. As we continue to advance our clinical pipeline and focus on oncology, we believe our resilience and ability to persevere through 2021 while growing our leadership and expertise positions us well for potentially significant milestones in 2022."

07:35 EST Vision Marine provides update on E-motion powertrain initiatives - Vision Marine Technologies (VMAR) has provided an update on recent corporate developments. Vision Marine has secured key partnerships regarding the production and associated supply chain of our E-Motion 180E fully electric powertrain system: In order to secure orders from major original equipment manufacturers, Vision Marine completed a Manufacture & Supply agreement with Linamar/McLaren Engineering (LIMAF). Octillion Power System: Exclusive Usage of High Density Batteries Designed Solely for The Boating Industry. Vision Marine executed a partnership with Octillion Power Systems, an advanced global supplier, designer, and builder of specialized high density lithium-ion electric vehicle battery systems. This will mark Octillion's first partnership in the marine industry, having delivered nearly 400,000 EV battery systems worldwide, with a focus on passenger cars, trucks, and buses.Vision Marine has partnered with Nextfour Solutions to further develop a customized multifunctional center console display to be integrated within Vision Marine's E-Motion 180E powertrain system. Electric Boat Rental Operations in Lido Marina, Newport Beach, CA: Starting with a small fleet of just four boats in 2017, Vision Marine now showcases 30 boats, with 5 more to be added by the end of the first quarter 2022. In 2020, the rental business serviced more than 8,000 customers.

07:33 EST Vanda trading halted, news pending

07:32 EST Cytokinetics announces FDA acceptance of NDA for omecamtiv mecarbil - Cytokinetics announced that the U.S. Food & Drug Administration has accepted and filed the company's New Drug Application for omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for the treatment of heart failure with reduced ejection fraction. The FDA assigned the NDA a standard review with a Prescription Drug User Fee Act target action date of November 30, 2022. The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application. The NDA is supported by the results from GALACTIC-HF, the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil that enrolled over 8,000 patients in 35 countries across 945 sites. GALACTIC-HF demonstrated a statistically significant effect of treatment with omecamtiv mecarbil to reduce risk of the primary composite endpoint of cardiovascular death or heart failure events compared to placebo in patients treated with standard of care. Additional analyses from GALACTIC-HF demonstrated a greater treatment effect of omecamtiv mecarbil in patients with lower left ventricular ejection fraction, as well as other characteristics that may indicate worsening heart failure.

07:27 EST NFI Group receives order from NJ Transit for eight Xcelsior CHARGE NG buses - NFI Group announced that its subsidiary New Flyer of America has received a firm order from the New Jersey Transit Corporation for eight zero-emission, next generation Xcelsior CHARGE NG forty-foot heavy-duty transit buses with options to purchase up to 75 more battery-electric buses under a five-year contract. The new contract advances NJ TRANSIT's zero-emission bus program to reach the goal of transitioning to a 100% ZEB fleet by 2040, aligned with Governor Murphy's Energy Master Plan.

07:13 EST Prospect Capital says preferred stock offerings exceeded $500M - Prospect Capital Corporation announced that Prospect's preferred stock offerings have exceeded $500M in aggregate liquidation preference issuances since the initial closing in the quarter ending December 31, 2020.

07:09 EST PyroGenesis announces resignation of director Rodney Beveridge - The company regretfully announces that it has been forced to accept the resignation of a Member of the Board of Directors Rodney Beveridge. Mr. Beveridge has been an important contributor to PyroGenesis' success. Mr. Beveridge's employer, the Toronto Dominion Bank (TD), demanded that Mr. Beveridge resign and, that the Company accept his resignation. TD made these demands in reference to a TD policy that precludes their brokers from sitting on public company boards. TD had originally approved Mr. Beveridge's request to sit on PyroGenesis' Board.

07:06 EST Green Plains announces intention to declassify board of directors - Green Plains announced that the Board of Directors has unanimously agreed to put forward a proposal to the Company's shareholders for a vote at its Annual Shareholder Meeting in May of 2022 to declassify the Board. Green Plains' directors are currently divided into three classes, with the members serving staggered three-year terms. Up until January 1, 2022, Iowa law, which applies to the Company as an Iowa corporation, required that the Company's Board remain classified. "Our recent initiatives to refresh the Board of Directors, update our bylaws and this proposal to declassify the Board reflect our commitment to strong corporate governance practices," said Kimberly Wagner, Chair of the Green Plains Nominating and Governance Committee. "After the recent change in Iowa law, and in consultation with several of our top shareholders, the nominating and governance committee proposed this change to the Board. We are pleased to be the first Iowa corporation of which we are aware to act on this new opportunity to further enhance shareholder rights."

07:03 EST Bristol-Myers reaffirms long-term financial targets - Bristol Myers Squibb is reaffirming its previously communicated 2020-2025 long-term targets: Expects low- to mid-single digit revenue CAGR and low double-digit revenue CAGR for its Continuing Business at constant exchange rates; Expects to maintain low- to mid-40s percent non-GAAP operating margin; Expects significant free cash flow generation of $45-$50 billion dollars from 2022-2024.

07:02 EST Vanda Pharmaceuticals: Phase 3 tradipitant study did not meet primary endpoint - Vanda Pharmaceuticals announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the efficacy and safety of tradipitant in treating the symptoms of gastroparesis. The study did not meet its prespecified primary endpoint which was the difference between drug and placebo on the change of the severity of nausea from baseline at week 12 of treatment. Both treatment arms showed significant improvements from baseline on nausea as well as the other core symptoms of gastroparesis. Initial exploratory analysis has identified potential confounders that may have masked the beneficial effect of the drug previously observed in the Phase II study of tradipitant, which include a baseline imbalance of rescue medication use between the two treatment arms as well as an observed poor compliance with study drug for some patients in the study. When restricting the analysis in the group of patients that used no rescue medications at baseline and adjusting for poor compliance, Vanda identified strong evidence of a drug effect across a number of symptoms and across the duration of the study, including a significant and meaningful effect at the prespecified primary endpoint of nausea change at week 12. The Phase III study also continued to demonstrate that tradipitant is safe and well-tolerated, as seen in previous studies over the 12 weeks of treatment. Patients on tradipitant experienced a similar number of treatment emergent adverse events as patients receiving placebo. The most common adverse event where tradipitant frequency was higher than placebo was diarrhea. Patients that participated in the clinical program also had the opportunity to seek expanded access to tradipitant based on the benefit in the study and their individual unmet medical needs. Ten patients have received more than 3 months of tradipitant treatment, 6 of whom have received at least 1 year of tradipitant treatment. Vanda plans to continue the analysis of the data of this study and prepare the results for submission to peer review journals as well as prepare the data for submission to regulatory authorities.

07:01 EST Pennsylvania REIT announces Springfield Town Center to launch Lego Center - PREIT announced that Springfield Town Center has executed an agreement with Merlin Entertainments to launch the next generation of Lego Discovery Center in 2023. The 32,000 square foot indoor attraction has been co-created by Merlin & the Lego Group and will be accessible on one level right off the main entrance to the property.

06:48 EST GrafTech sees itself well positioned in FY22 - The company said, "The steel industry has experienced unprecedented pricing over the past 12 months. While pricing has retreated recently, it remains well above historical levels and the near-term fundamentals in the steel industry remain strong. More broadly, the industry is continuing to look for ways to de-carbonize and many of these efforts are focused on moving away from traditional blast furnace production to electric arc furnace steel production. GrafTech is well-positioned to benefit from these events in 2022 and beyond."

06:42 EST Mallinckrodt wins court approval to settle opioid-related liabilities for $1.7B - Mallinckrodt sought approval of the Fourth Amended Joint Plan of Reorganization of the company and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. Hearings to consider the Plan and the objections to confirmation were held over sixteen days between November 2021 and January 2022. "I have reviewed the Plan and the evidence presented in support and in opposition, and... I find that the Plan satisfies all the requirements of the Bankruptcy Code, and it is therefore confirmed," Judge John Dorsey of the U.S. Bankruptcy Court in Wilmington, Delaware wrote. Judge Dorsey also released the company of legal liability, writing, "The weight of the evidence before me suggests that these releases are not only necessary and fair, but overwhelmingly supported by the creditor body." Mallinckrodt will settle its opioid-related liabilities for $1.725B, which will be paid over 8 years. Reference Link

06:38 EST Regeneron sees FY22 gross margin on net product sales 90%-92% - Sees FY22 effective tax rate 13%-15%.

06:23 EST Sculptor Capital comments on director resignation due to governance disagreement - In a regulatory filing last night, J. Morgan Rutman resigned from the board of directors of Sculptor Capital stating that he was doing so due to a disagreement over board governance, principally related to executive compensation, as detailed in his resignation letter. Rutman was a director appointed by the company's founding CEO pursuant to an agreement entered into at the time of his separation from the company in early 2019. Rutman is employed as the president of the former CEO's personal investment firm, a position he has held for over a decade. In response to Rutman's resignation letter, the four independent members of the company's board of directors stated the following: "Mr. Rutman's letter is filled with significant factual inaccuracies, material omissions and baseless assertions that present a misleading view of Board governance, including the careful and extensive process and analysis engaged in by the Compensation Committee as well as the conclusions of Semler Brossy, the Committee's independent compensation consultant. Mr. Rutman selectively quotes from the Semler report to distort Semler's positions, and notably he omits Semler's conclusion: "On balance, we believe the Proposals are reasonable when viewed within the context of the: (i) extraordinary and unique nature of the Company's ongoing transformation, and (ii) the Committee's stated objectives for the compensation arrangements." As to process, members of the Compensation Committee held dozens of meetings over a four-month period, including over 15 with Semler. At the conclusion of that months-long process, all of the independent directors, other than Mr. Rutman, believed that the compensation arrangements were in the best interests of the Company and its shareholders, and voted to approve. The Company and the Board remain focused on delivering for shareholders and being outstanding stewards of our fund investors' capital. We are extremely proud of the Company's talented and dedicated management team, the many successes they have achieved for the Company, and the trajectory of the Company."

05:22 EST Arena Group to uplist to NYSE on February 9 - theMaven, currently operating under the brand name Arena Group, announced that it anticipates uplisting its common stock to the NYSE American under the symbol (AREN) and anticipates effecting a name change and a 1-for-22 reverse stock split of its common stock, par value $0.01 per share. The new corporate name for the company will be Arena Group and the company will do business as Arena Group. The first date of trading on the NYSE American is expected to be February 9.

05:17 EST Kennedy Wilson acquires Waverleygate building in Scotland for $106M - Kennedy Wilson has acquired Waverleygate, a wholly-owned prime office building in Edinburgh, from the real assets investment manager Patrizia for $106M, excluding closing costs. With a Class A vacancy rate in Edinburgh City Centre of 2%, Kennedy Wilson will invest in the property to provide amenities.

05:12 EST Puxin Limited evaluates plan to enter fast-food chain restaurant business - Puxin Limited announced that it is evaluating opportunities to expand its existing business by entering into the fast-food chain restaurants business in China. The company possesses an integration capability and expects that its Puxin Business System, which covers 3,000 management modules, would allow it to optimize the operating system and business performance of existing restaurants. The company also expects that its involvement will support the restaurants to improve customers traffic by opening new locations around or inside the company's schools. No assurance can be provided that the company will complete a transaction in the identified industry.

05:08 EST Fortuna Silver Mines seeks clarification from Mexican authorities on EIA - Fortuna Silver Mines reported that it received a notice from the Secretaria de Medio Ambiente y Recursos Naturales, or SEMARNAT, which advised that SEMARNAT has made a typographical error in the extension to the term of the environmental impact authorization, or EIA, for the San Jose Mine, located in Oaxaca, Mexico. On December 17, 2021, SEMARNAT granted the company a 12 year extension to the EIA for the San Jose Mine which expires in October 2033. However, the notice states that SEMARNAT has made a typographical error in the EIA extension and that the correct term is two years. The company is of the view that the notice was issued by the local office of SEMARNAT in error. Fortuna's Mexican subsidiary, Compania Minera Cuzcatlan is working with authorities to resolve this matter. In addition, Minera Cuzcatlan has initiated legal proceedings in the Federal Court to challenge and revoke said typographical error and to reconfirm the 12 year extension period granted by SEMARNAT in December 2021.